Novo’s Weight Loss Drugs Removed from FDA Shortage List
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.
David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
Senators questioned Novo Nordisk CEO Lars Jørgensen on Tuesday at a hearing over the costs of Ozempic, Wegovy and similar weight loss drugs, which are cheaper in other countries. The CEO of ...
Local companies are developing technologies that they hope could replace a painful poke with something that feels more like ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback